The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:2078-2079 November 20, 2003 Number 21
NextNext

Treatment of HCV-Related Mantle-Cell Lymphoma with Ribavirin and Pegylated Interferon Alfa

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: We expand on the data presented by Hermine et al., who demonstrated the antitumor efficacy of interferon alfa in hepatitis C virus (HCV)–infected patients with marginal-zone lymphoma.1 We report the details of anti-HCV therapy in the patient from whom we established a B lymphoma cell line that is persistently infected with HCV.2 In culture, the line continuously produces HCV, which can infect primary human hepatocytes, peripheral-blood mononuclear cells, and Raji cells.

In 1995, this patient, a 66-year-old man, was found to have cryoglobulinemia, with elevated levels of rheumatoid factor and creatinine. Antibody to HCV was present; the . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.